摘要
目的探讨达雷妥尤单抗联合IRd方案治疗复发难治性多发性骨髓瘤(RRMM)患者的效果。方法选取2019年6月至2022年6月我院收治的66例RRMM患者,随机分为两组。参照组接受IRd方案(伊沙佐米+地塞米松+来那度胺)治疗,研究组在参照组治疗基础上联合达雷妥尤单抗治疗,比较两组的临床疗效、不良反应以及复发率。结果治疗8个疗程后,研究组的总缓解率为93.94%,明显高于参照组的57.58%(P<0.05)。治疗期间,研究组的不良反应总发生率(63.64%)与参照组(45.45%)比较,差异无统计学意义(P>0.05)。治疗后随访3个月期间,研究组的复发率为6.45%,明显低于参照组的52.63%(P<0.05)。结论达雷妥尤单抗联合IRd方案治疗RRMM患者的效果显著,有助于降低复发率,且未明显增加不良反应的发生。
Objective To explore the effect of daleituzumab combined with IRd regimen in the treatment of patients with relapsed and refractory multiple myeloma(RRMM).Methods A total of 66 patients with RRMM admitted to our hospital from June 2019 to June2022 were selected and randomly divided into two groups.The reference group was treated with IRd regimen(ixazomib+dexamethasone+lenalidomide),and the study group was treated with dasatuzumab on the basis of the reference group.The clinical efficacy,adverse reactions and recurrence rate were compared between the two groups.Results After 8 courses of treatment,the total remission rate of the study group was 93.94%,significantly higher than 57.58%of the reference group(P<0.05).During the treatment period,no significant difference was found in the total incidence of adverse reactions between the study group(63.64%)and the reference group(45.45%),P>0.05.During the3-month follow-up period after treatment,the recurrence rate of the study group was 6.45%,significantly lower than 52.63%of the reference group(P<0.05).Conclusions Daleituzumab combined with IRd regimen in the treatment of patients with RRMM has significant effect,which helps to reduce the recurrence rate and does not obviously increase the occurrence of adverse reactions.
作者
肖晶晶
毛沛沛
乔莎
XIAO Jinging;MAO Peipei;QIAO Sha(Department of Hematology,Nanyang Central Hospital,Nanyang 473000,China)
出处
《临床医学工程》
2024年第6期693-694,共2页
Clinical Medicine & Engineering
